Want to join the conversation?
$NVDA 1Q16 10-Q: Research and development expenses were $339MM at April 26, 2015, relatively flat vs. 1Q15. Compensation and benefits increased by $21MM. Sales, general and administrative expenses increased 16% compared to 1Q15. Outside professional fees increased, due to $16MM of legal fees associated with litigation against Samsung and Qualcomm.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.